SMART MONEY GROUP

[ospreyeye]

SRPT: The analyst added, “High beta, small cap biotechnology stocks have suffered disproportionate declines over the past few months, and are creating very attractive entry points for long-term investors. We would recommend buying Sarepta at current levels as we continue to believe that eteplirsen is biologically active and SRPT’s PMO-platform is best-in-class.”

nice $30 price target.........thanks for the link..........$$$